SynthesisThe American journal of gastroenterology2017
Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis.
Synthesis in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.Health technology assessment (Winchester, England) · 2022Pooled it
- Guideline
- A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome.Scientific reports · 2022Pooled it
- The accuracy of diagnostic indicators for coeliac disease: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Irritable Bowel Syndrome and Gluten-Related Disorders.Nutrients · 2020Pooled it
- The Epidemiology of Celiac Disease in the General Population and High-Risk Groups in Arab Countries: A Systematic Review.BioMed research international · 2020Pooled it
- A Patient-Centered Ethical Framework for Irritable Bowel Syndrome Care: Communication, Trust, Nutrition-Sensitive Care, and Self-Management.Nutrients · 2026Review
- Stability of Classification Systems for Irritable Bowel Syndrome.Alimentary pharmacology & therapeutics · 2026Article
- Psychosomatic Features of Irritable Bowel Syndrome: The Role of Alexithymia in Patient Health-Related Quality of Life-A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Subtle Laboratory and Clinical Precursors of Celiac Disease in Young Adults: A Large-Scale Retrospective Cohort Study.Journal of general internal medicine · 2026Article
- Overlap of Structural Gastrointestinal Disorders in Children With Disorders of Gut-Brain Interaction.Neurogastroenterology and motility · 2026Review
- Stress, Diet, and Sleep Shape Irritable-Bowel-Syndrome-Specific Symptoms: The Lockdown "Cocoon Effect".Journal of clinical medicine · 2025Article
- The Clinical Registry of Childhood Asthma (CRCA) Elucidating Early-Life Asthma: Cross-Sectional Analysis of a Prospective, Longitudinal, and Digitally Enhanced Real-World Cohort.Journal of medical Internet research · 2025Article
- Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights.International journal of molecular sciences · 2025Review
- Endoscopy and noninvasive tests in pediatric disorders of gut-brain interaction: A multicenter retrospective study of the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition.Journal of pediatric gastroenterology and nutrition · 2025Article
- Celiac disease diagnosis in clinical practice: ESPGHAN quality of care survey from 129 pediatric hospitals across 28 countries.Journal of pediatric gastroenterology and nutrition · 2025Article
- Genome-Wide DNA Methylation Identifies Potential Disease-Specific Biomarkers and Pathophysiologic Mechanisms in Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Celiac Disease.Neurogastroenterology and motility · 2025Article
- Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care.Alimentary pharmacology & therapeutics · 2025Article
- A Systems Biology and Drug Repositioning Approach for the Analysis of Mutual Genes Between Celiac Disease and Irritable Bowel Syndrome.BioMed research international · 2025Article
- Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCeliac disease (CD) and irritable bowel syndrome (IBS) share similar symptoms, leading to confusion between the two and diagnostic delay. International guidelines recommend screening individuals with IBS for CD, via serological testing. However, studies published recently have cast doubt on the utility of this. We updated a previous meta-analysis examining this issue.
methodsMEDLINE, EMBASE, and EMBASE Classic were searched through to May 2016. Eligible studies recruited adults with IBS according to symptom-based criteria, physician's opinion, or questionnaire data. Tests for CD included IgA-class antigliadin antibodies (AGA), endomysial antibodies (EMA), tissue transglutaminase antibodies (tTG), or duodenal biopsies following positive serology. The proportion of individuals meeting criteria for IBS testing positive for CD was combined to give a pooled prevalence for all studies, and compared between cases with IBS and, healthy controls without (where reported), using an odds ratio (OR) with a 95% confidence interval (CI).
resultsThere were 36 eligible studies, recruiting 15,256 individuals, of whom 9,275 (60.8%) met criteria for IBS. Pooled ORs for positive IgA AGAs, EMA and/or tTG, and biopsy-proven CD in IBS subjects vs. controls were 3.21 (95% CI 1.55-6.65), 2.75 (95% CI 1.35-5.61), and 4.48 (95% CI 2.33-8.60), respectively. There was no increase in ORs for any test for CD among cases with IBS in North American studies, and results were inconsistent in population-based studies. The prevalence of biopsy-proven CD was significantly higher across all subtypes of IBS. Limitations included heterogeneity in some analyses, and few North American studies.
conclusionsOverall, prevalence of positive celiac serology and biopsy-proven CD was significantly higher in subjects with symptoms suggestive of IBS vs. healthy controls. However, the utility of screening for CD in individuals with suspected IBS in North America or in the community is less clear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.